KYMR

SEC source: 0001209191-22-055148 · doc4.xml · nonDerivative · entry 7

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,537,456

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.95 to $31.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend if his pecuniary interest therein, if any.

SEC source: 0001209191-22-055148 · doc4.xml · nonDerivative · entry 6

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,050,584

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-22-055148 · doc4.xml · nonDerivative · entry 5

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,541,183

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend if his pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 8

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,049,540

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.95 to $31.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 7

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,537,456

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.95 to $31.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 6

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,050,584

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 5

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,541,183

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-055148 · doc4.xml · nonDerivative · entry 4

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,066,388

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-22-055148 · doc4.xml · nonDerivative · entry 3

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,597,638

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend if his pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 4

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,066,388

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 3

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,597,638

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-055148 · doc4.xml · nonDerivative · entry 2

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,092,771

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-22-055148 · doc4.xml · nonDerivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,691,877

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend if his pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,092,771

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-22-055142 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,691,877

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000899243-22-033996 · doc4.xml · derivative · entry 2

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,899

Underlying: Common Stock · 10,000 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-22-033996 · doc4.xml · nonDerivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,279

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-033709 · doc4.xml · derivative · entry 4

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 546,604

Underlying: Common Stock · 27,676 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-22-033709 · doc4.xml · derivative · entry 3

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,368

Underlying: Common Stock · 32,056 shares

Expires 2029-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-22-033709 · doc4.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 561,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-033709 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 534,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-033710 · doc4.xml · derivative · entry 2

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,899

Underlying: Common Stock · 10,000 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-22-033710 · doc4.xml · nonDerivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,279

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes 465 shares acquired under the Registrant's employee stock purchase plan on May 31, 2022.

SEC source: 0000921895-22-002524 · form407422010_08232022.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 257,754

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-22-002524 · form407422010_08232022.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,861,290

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-22-002524 · form407422010_08232022.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,480,742

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000899243-22-025817 · doc4.xml · derivative · entry 1

Morgan Leigh · CIK 0001935887 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2032-07-05

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on July 6, 2022..

SEC source: 0000899243-22-024748 · doc4.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2032-06-28

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on June 29, 2022.

SEC source: 0000899243-22-022797 · doc4.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F2 · ownership.direct: The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-22-022796 · doc4.xml · derivative · entry 1

Nicholson Donald William · CIK 0001814617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-022795 · doc4.xml · derivative · entry 1

Esposito Pamela · CIK 0001744425 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-022792 · doc4.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-022791 · doc4.xml · derivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-22-022789 · doc4.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-022788 · doc4.xml · derivative · entry 1

Horobin Joanna · CIK 0001560959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000921895-22-002030 · form407422010_06172022.xml · derivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 12,000

Underlying: Common Stock, $0.0001 par value · 12,000 shares

Expires 2032-06-14

F6 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F8 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F6 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F6 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0000921895-22-001847 · form407422010_05312022.xml · nonDerivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,637

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-22-001847 · form407422010_05312022.xml · nonDerivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,627,928

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-22-001847 · form407422010_05312022.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,195,696

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000921895-22-001847 · form407422010_05312022.xml · nonDerivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,414

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-22-001847 · form407422010_05312022.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,601,575

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-22-001847 · form407422010_05312022.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,159,903

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000921895-22-001781 · form407422010_05242022.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,772

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-22-001781 · form407422010_05242022.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,511,203

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-22-001781 · form407422010_05242022.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,036,860

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000921895-22-001520 · form407422010_05092022.xml · nonDerivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,735

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-22-001520 · form407422010_05092022.xml · nonDerivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,507,023

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-22-001520 · form407422010_05092022.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,030,977

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000921895-22-001520 · form407422010_05092022.xml · nonDerivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,604

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-22-001520 · form407422010_05092022.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,466,364

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.